Mirum Pharmaceuticals, Inc. (MIRM) · Sep 8, 2026 · Exec change

Mirum replaces CMO after abrupt exit, adding clinical-execution uncertainty

CMO transition — Rob Myers starts Sept. 21; Joanne Quan separation expected Oct. 19

Mirum is replacing Chief Medical Officer Joanne Quan with Rob Myers after her immediate departure from the role. The transition is orderly, but the surprise turnover adds execution risk.

The filing introduces an unexpected clinical-leadership change. Joanne Quan stopped serving as chief medical officer on September 2, while Rob Myers is expected to begin employment on September 21. 〔0〕 With no published operating or financial benchmark for an executive transition, the relevant comparison is the standing assumption of continuity: this is a new disruption rather than a routine confirmation.

The replacement limits the disruption but does not eliminate the execution question. The handoff is planned rather than an open-ended vacancy, since the company has already appointed Rob Myers as successor. 〔1〕 Still, the filing gives no reason for Quan’s departure and provides no detail on Myers’ priorities, experience, or expected impact on Mirum’s clinical programs, leaving the operational significance unclear.

The severance terms make this a real personnel transition, not a title change. Mirum expects to provide plan-based severance, extend the exercise period for Quan’s vested options to 12 months after separation, and pay her 2026 target bonus at 100% achievement, subject to customary conditions. 〔2〕 Net, the named successor keeps the event manageable, but the sudden CMO turnover is modestly worse than an investor would have expected from a continuity assumption.

What to watch next

Rob Myers begins as chief medical officer, September 21

Original filing on SEC EDGAR

More Mirum Pharmaceuticals, Inc. news

Mirum replaces CMO after abrupt exit, adding clinical-execution uncertainty | MIRM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.